Webinar Date/Time: Option 1: Thursday, February 1st, 2024 at 9am EST | 6am PST | 2pm GMT | 3pm CET Option 2: Thursday, February 1st, 2024 at 2pm EST | 11am PST | 7pm GMT | 8pm CET
Are you interested in learning about clinical trial forecasting and site payment best practices? Join IQVIA Technologies to learn how innovative technology can provide a comprehensive solution for managing finances in complex trials.
Register Free: https://www.appliedclinicaltrialsonline.com/act/forecasting-and-payments
Event overview
Join IQVIA Technologies for an informative webinar exploring the intricacies of clinical trial budget forecasting and payments. As trials continue to grow in complexity and scale, understanding budget forecasting best practices and site payment needs is crucial.
This presentation considers the complexities of conducting trials across multiple countries and sites, the increasing prevalence of protocol amendments, and the growing demand for timely payments. Don’t miss your chance to learn about strategies to manage trial payments, effective forecasting methods, and how technology can provide a comprehensive solution for managing trial finances.
Three key take-aways
In this webinar, you'll learn...
Speakers:
Rajiv Prasad
Director, Financial Forecasting, Clinical Trial Payments
IQVIA Technologies
Rajiv Prasad has more than 25 years’ experience in information technology, product development, finance, strategy, and operations management. At IQVIA Technologies, Rajiv leads a team focused on automating and systematizing the forecasting of investigator grant activity and payments. Prior to IQVIA, he held technology leadership positions at Sutherland Global and Unisys, developing and implementing systems, products, and services portfolios. Rajiv holds a BE in Electrical Engineering from IIT Roorkee and a master’s degree in industrial engineering from IIM Bombay.
Jim DiCesare
Senior Director, Study Operations, Clinical Trial Payments
IQVIA Technologies
Jim DiCesare is passionate about delivering innovative Cost Benchmarking, CTA Negotiation and Site Payment services that support the clinical research conducted by sponsors and CROs. With over 25 years of industry experience leading clinical operations teams at Merck, DrugDev, and now IQVIA Technologies, Jim has expertise across the contracting, budgeting, and investigator grant payment management continuum. He is a frequent speaker at industry conferences and has written for a variety of publications. He has a B.S. in Accounting from Kutztown University.
Register Free: https://www.appliedclinicaltrialsonline.com/act/forecasting-and-payments
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
FDA to Launch National Priority Voucher Program to Speed Drug Reviews for Critical Therapies
June 18th 2025Under the new initiative, companies may receive a voucher enabling FDA review to be shortened from the standard 10–12 months to just 1–2 months following final application submission if the drug addresses US national health priorities.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
FDA to Launch National Priority Voucher Program to Speed Drug Reviews for Critical Therapies
June 18th 2025Under the new initiative, companies may receive a voucher enabling FDA review to be shortened from the standard 10–12 months to just 1–2 months following final application submission if the drug addresses US national health priorities.
2 Commerce Drive
Cranbury, NJ 08512